Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVATAR: Bevacizumab in advanced gastric cancer
NCT00887822Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2009
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) comparing Bevacizumab Arm with Placebo Arm (2 arms). Primary endpoints: Overall Survival up to 34 months and Percentage of Participants With Event (Death) up to 34 months. Started Mar 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00887822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887822.